---
schema_version: "secwatch.filing_event.v1"
accession: "0001773751-26-000033"
form_type: "8-K"
ticker: "HIMS"
cik: "0001773751"
company_name: "Hims & Hers Health, Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:54:32.313743+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hims & Hers partners with Novo Nordisk, shifts US weight loss strategy to FDA-approved GLP-1s

## Summary
- Collaboration with Novo Nordisk to offer Ozempic and Wegovy on platform starting March 2026.
- Will no longer advertise compounded GLP-1s; limited compounding only for clinical necessity.
- Novo Nordisk dismisses its lawsuit against Hims & Hers without prejudice.
- Existing patients can transition to FDA-approved GLP-1s when clinically appropriate.
- CEO Dudum: partnership enables scaled distribution of innovations for affordable access.

## SEC filing metadata
- accession: 0001773751-26-000033
- form_type: 8-K
- ticker: HIMS
- cik: 0001773751
- company_name: Hims & Hers Health, Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1773751/000177375126000033/0001773751-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1773751/000177375126000033/hims-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001773751-26-000033
- JSON: https://secwatch.observer/filing/0001773751-26-000033.json
- Plain text: https://secwatch.observer/filing/0001773751-26-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.